Record Q2 Revenue and Defense Backlog Offset Neutron Delay Concerns, But Margin and Financing Risks Keep Valuation Full

What happened

Rocket Lab reported record Q2 revenue of $234 million, gross margin improvement, and backlog growth to $2.36 billion, driven by a $456 million suborbital defense contract that does not require Neutron and demonstrates competitive wins against legacy contractors. Management guided for another record Q3, with 45.5% of backlog expected to convert within a year, signaling strong near-term demand. However, the master report highlights that Q3 gross margin guidance of 29-31% and negative adjusted EBITDA reflect margin pressure from contract mix and Neutron development costs. Neutron’s first launch remains uncertain with only pad delivery targeted for Q4 2026, and the proposed Iridium acquisition adds financing and dilution risk. While the Seeking Alpha article reaffirms a Strong Buy, the base case sees the stock at $72.60 as adequately pricing in near-term positives, warranting a WAIT for better entry.

Implication

The record backlog and defense momentum are real, but investors must distinguish between contract wins and cash-generating revenue, especially as free cash flow turned negative in Q2. Watch for Neutron milestones: management must shift from 'pad delivery' language to a concrete first-flight date to validate 2027 medium-lift assumptions. Gross margin staying below 30% for two consecutive quarters would signal that scale is not translating into operating leverage, undermining the platform thesis. The Iridium acquisition's permanent financing terms should be scrutinized for excessive dilution or restrictions on Neutron funding; any sign of distress would warrant reducing exposure. Until these uncertainties resolve, the stock offers balanced risk-reward with a bear case of $52 and a bull case of $92, making patience prudent.

Thesis delta

There is no material shift in the investment thesis. The positive article reinforces existing revenue and backlog strengths, but does not alter the core risks: Neutron schedule uncertainty, margin compression, and Iridium financing risk. No new evidence of Neutron acceleration or margin recovery has emerged, so the balanced risk-reward persists.